Cargando…

Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers

BACKGROUND: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tinker, AV, Speers, C, Barnett, J, Olivotto, IA, Chia, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234069/ https://www.ncbi.nlm.nih.gov/pubmed/22275960 http://dx.doi.org/10.3332/eCMS.2008.63

Ejemplares similares

Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer
por: Goldrick, A., et al.
Publicado: (2007)

Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
por: Fucà, Giovanni, et al.
Publicado: (2020)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
por: Berliere, Martine, et al.
Publicado: (2008)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
por: Biesaga, Beata, et al.
Publicado: (2014)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas
por: Tőkés, Anna Mária, et al.
Publicado: (2022)

Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy
por: Tzolos, E., et al.
Publicado: (2020)

Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy
por: LIU, WENJUAN, et al.
Publicado: (2015)

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
por: Aspinall, Sherrie L, et al.
Publicado: (2015)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
por: LeVasseur, N, et al.
Publicado: (2017)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
por: Castoldi, Francesca, et al.
Publicado: (2018)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
por: Brain, E., et al.
Publicado: (1997)

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
por: Absmaier, Magdalena, et al.
Publicado: (2018)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
por: Xu, Y. L., et al.
Publicado: (2017)

Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy
por: Lee, Kyuwan, et al.
Publicado: (2020)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II
por: Horvat, Matej, et al.
Publicado: (2016)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
por: Liu, Minetta C, et al.
Publicado: (2016)

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
por: Kim, In-Ho, et al.
Publicado: (2017)

Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience
por: Liu, Shiru L., et al.
Publicado: (2019)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
por: Kim, Seong-Geun, et al.
Publicado: (2016)

Adjuvant Chemotherapy and Tumor Sidedness in Stage II Colon Cancer: Analysis of the National Cancer Data Base
por: Mukkamalla, Shiva Kumar R., et al.
Publicado: (2020)

Anthracycline dose and liver dysfunction
por: Cannizzaro, R, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_jub4nktq0dmat9bacad3t13lf6